Early data on Moderna's COVID-19 vaccine insufficient: Stat News
Tweet
Share
E-mail
A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder
Get Alerts MRNA Hot Sheet
Join SI Premium – FREE
(Reuters) - Data from a small, early-stage safety trial testing Moderna Inc's (NASDAQ: MRNA) experimental COVID-19 vaccine does not provide critical data to assess its effectiveness, Stat News reported on Tuesday, citing experts.
The health news publication's report https://bit.ly/36kKerh pulled down shares of the Cambridge, Massachusetts-based biotech and erased modest gains on the benchmark S&P 500 index <.SPX>.
Moderna said on Monday the vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers.
The news based on data from eight people who took part in a 45-subject safety trial sent the company's shares up nearly 20% on Monday and also pushed the markets higher.
Moderna did not immediately respond to a Reuters' request for comment.
The company's shares closed down 10.4% at $71.67.
(The story corrects shares close to $71.67, from 471.67, in last paragraph)
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equity risk premium falls to 2002 levels. What it means for stocks
- Premarket movers: Oracle surges on AI growth, ACV auctions jumps on $1.9B deal
- 'No panic anywhere' may be the problem, BofA strategists warn
Create E-mail Alert Related Categories
General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
